REG - IXICO plc - Update regarding Nominated Adviser and Broker

IXICOAnnouncement

27/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231227:nRSa8387Xa&default-theme=true

RNS Number : 8387X  IXICO plc  27 December 2023

27 December 2023

 

 

IXICO plc

("IXICO" or the "Company")

 

Update regarding Nominated Adviser and Broker

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience, announces that, following the completion
of the all-share merger between Cavendish Securities plc (previously named
Cenkos Securities plc) and Cavendish Financial plc (previously named finnCap
Group plc), and as a consequence of internal reorganisation within the
Cavendish Group, the Company has changed its Nominated Adviser and Broker from
Cavendish Securities plc to Cavendish Capital Markets Limited.

 

 For further information please contact:

IXICO plc                                                                                +44 (0) 20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)                    +44 (0) 20 7220 0500
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

 About IXICO

 IXICO is dedicated to delivering insights in neuroscience to help transform
 the advancement of investigational therapies for neurological diseases, such
 as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
 Company's purpose is to advance medicine and human health by turning data into
 clinically meaningful information, providing valuable new insights in
 neuroscience by supporting pharmaceutical companies across all phases of CNS
 clinical research. IXICO's goal is to be a leading advocate of artificial
 intelligence in medical image analysis.

 IXICO has developed and deployed breakthrough data analytics, at scale,
 through its remote access technology platform, to improve the return on
 investment in drug development and reduce risk and uncertainty in clinical
 trials for the Company's pharmaceutical clients.

 More information is available on www.IXICO.com (http://www.ixico.com/)  and
 follow us on Twitter @IXICOnews

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.ixico.com/)  and
follow us on Twitter @IXICOnews

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFLFSRFDLFFIV